Immunotherapy Advances: Earlier Use Shows Promise Across Multiple Cancers
Immunotherapy is increasingly being utilized earlier in the treatment of several cancer types, both before and after surgery, offering new hope for improved outcomes. A comprehensive review published in the Journal of Internal Medicine highlights the evolving landscape of immunotherapy and its potential benefits across a range of tumors.
The Shift Towards Earlier Intervention
For years, immunotherapy has revolutionized the treatment of advanced cancers that are no longer amenable to surgical removal. Now, its application is expanding to earlier stages of disease, implemented as neoadjuvant therapy (before surgery) or adjuvant therapy (after surgery). Researchers at Karolinska Institutet have summarized findings from studies across seven tumor areas: skin cancer, lung cancer, breast cancer, gastrointestinal cancer, gynecological cancer, head and neck cancer and urological cancer. Karolinska Institutet
Benefits of Pre- and Post-Surgery Immunotherapy
Studies demonstrate that adjuvant immunotherapy following surgery can reduce the risk of cancer recurrence. Neoadjuvant treatment, administered even as the tumor is still present, can enhance the immune system’s ability to recognize and target cancer cells. In several cancer types, combining neoadjuvant and adjuvant immunotherapy may provide advantages over adjuvant treatment alone. PubMed
Cancer Types Under Review
The review encompassed a broad spectrum of cancers, including:
- Skin Cancer
- Lung Cancer
- Breast Cancer
- Gastrointestinal Cancer
- Gynecological Cancer
- Head and Neck Cancer
- Urological Cancer
Challenges and Considerations
While promising, the researchers emphasize that the effectiveness of immunotherapy varies depending on the specific cancer type. Challenges remain, including the risk of side effects and the potential for overtreatment – administering immunotherapy when surgery alone might have been sufficient. Mirage News
The Need for Biomarkers
A key area for future research is the development of biomarkers – measurable characteristics that can predict which patients will benefit most from immunotherapy, both before and after surgery. Identifying these biomarkers will be crucial for personalizing treatment and maximizing its effectiveness.
Cost, Resources, and Long-Term Effects
The introduction of immunotherapy at earlier stages also raises essential questions about healthcare costs, the management of immune-related adverse events (occurring in up to 30% of patients), and the long-term sustainability of healthcare resources. Further studies are needed to address these concerns. PubMed
Expert Perspective
“We see that immunotherapy in early stages of disease is developing rapidly across many tumor areas. By bringing together studies from many cancer types, it becomes clearer how the field is evolving and what experiences can be shared between different specialties,” says Hildur Helgadottir, researcher at the Department of Oncology-Pathology at Karolinska Institutet.
Looking Ahead
The integration of immunotherapy into perioperative cancer management represents a significant advancement in curative-intent oncology. Ongoing research, biomarker development, and adaptive trial designs will be essential to optimize its use and ensure that patients receive the most effective and personalized treatment possible.